ANAB

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing immunology therapeutics for inflammatory and immune-related diseases. Headquartered in San Diego, California, the company operates as a drug discovery and development enterprise specializing in antibody-based therapies. AnaptysBio's pipeline includes rosnilimab, an anti-PD-1 agonist antibody in development for moderate-to-severe atopic dermatitis and other inflammatory conditions, and imsidolimab, an anti-IL-36R antibody targeting generalized pustular psoriasis and other rare inflammatory diseases. The company utilizes its proprietary antibody discovery platform to generate therapeutic candidates addressing significant unmet medical needs in immunology. In 2023, AnaptysBio reported positive Phase 2b data for rosnilimab in atopic dermatitis patients, advancing the compound toward potential pivotal trials. The company also maintains strategic partnerships with major pharmaceutical organizations, including a prior collaboration with Celgene Corporation that generated substantial milestone payments. AnaptysBio operates with a streamlined organizational structure typical of clinical-stage biotech firms, focusing resources on advancing its lead programs through clinical development. The company went public in 2017 and trades on the NASDAQ under the ticker ANAB. Its business model centers on either independently developing drug candidates through commercialization or establishing partnerships for late-stage development and marketing rights, providing multiple pathways to value creation.